Differential expression of cerebellar metabotropic glutamate receptors mGLUR2/3 and mGLUR4a after the administration of a convulsant drug and the adenosine analogue cyclopentyladenosine.
Metabotropic glutamate receptors (mGluR) play a role in synaptic transmission, neuronal modulation and plasticity but their action in epileptic activity is still controversial. On the other hand adenosine acts as a neuromodulator with endogenous anticonvulsive properties. Since cerebellum from epileptic patients has shown neuronal damage, sometimes associated with Purkinje cells loss, we have explored the effect of repetitive seizures on two types of mGluR in the cerebellum. Seizures were induced by the convulsant drug 3-mercaptopropionic acid (MP) and the effect of the adenosine analogue cyclopentyladenosine (CPA) alone or before MP administration (CPA+MP) were also evaluated. The expression of the receptors subtypes 2/3 (mGluR2/3) and 4a (mGluR4a) was assessed by immunocitochemistry. Granular cell layer was labeled with mGluR2/3 antibody and increased immunoreactivity was observed after MP (60%), CPA (53%) and CPA + MP (85%) treatments. Control cerebellum slices showed mGluR4a reactivity around Purkinje cells, while MP, CPA and CPA+MP treatment decreased this immunostaining. Repetitive administration of MP and CPA induces an increased cerebellar mGluR2/3 and a decreased mGluR4a immunostaining, suggesting a distinct participation of both receptors that may be related to the type of cell involved. A protective action and /or an apoptotic effect may not be discarded. CPA repetitive administration although increase seizure latency, cannot prevent seizure activity.
Girardi
Elena Silvia
ES
Instituto de Biología Celular y Neurociencia Prof. Eduardo De Robertis Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. egirardi@mail.retina.ar
Canitrot
Juan
J
Antonelli
Marta
M
González
Nélida N
NN
Coirini
Héctor
H
D015097:3-Mercaptopropionic Acid / Q000008:administration & dosage / Q000378:metabolism*; D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D002531:Cerebellum / Q000166:cytology / Q000378:metabolism*; D003292:Convulsants / Q000008:administration & dosage / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000235:genetics / Q000378:metabolism*
C088229:2-amino-4-phosphonobutyrate receptor; D003292:Convulsants; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3; C048599:N(6)-cyclopentyladenosine; D015097:3-Mercaptopropionic Acid; D000241:Adenosine